North America Genome Editing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CRISPR, TALEN, Antisense, and Other), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Clinical Research Organizations)
The genome editing market in North America is expected to grow from US$ 2,136.41 million in 2021 to US$ 7,024.71 million by 2028; it is estimated to grow at a CAGR of 18.5% from 2021 to 2028.
Over the past few years, advances in genome editing technologies have been making constant headlines. Genome editing technologies can alter biological research and significantly impact human health, food security, and environmental sustainability since they are precise, relatively inexpensive, easy to use, and remarkably powerful. The advances in genome editing can be traced back to quiet beginnings in the 1990s. The introduction of CRISPR-Cas9—a genome-editing tool that can be used to make precise and targeted changes in the DNA sequence with ease—is mainly responsible for the recent rise in the amount and scope of applications of genome editing technologies. The CRISPR platform's ease of use, as compared to previous technologies, has resulted in its widespread adoption and application. Genome editing could have a favorable impact on sustainable development, environmental management, food security, and the introduction of affordable diagnostics and therapies for various diseases due to these advancements. A team from MIT and Harvard's Broad Institute has developed a novel CRISPR genome-editing technique that has the potential to fix up to 89% of disease-causing genetic abnormalities. CRISPR-Cas9 and reverse transcriptase, two of the most significant proteins in molecular biology, have been merged into a single machine by researchers. Prime editing is a method that can alter human cells directly in a precise, efficient, and highly versatile manner. They have also developed a CRISPR RNA-cutting enzyme into an antiviral agent that can be programmed to detect and eliminate RNA-based viruses in human cells. The Cas13 enzyme has previously been used to cut and alter human RNA and as a diagnostic approach for detecting the presence of viruses, bacteria, and other targets. This is one of the first studies to use Cas13, or any CRISPR system, as an antiviral in human cells in culture. Recognizing the potential of genome editing techniques for studying and manipulating the genome, the DBT has been fostering research and innovation in genome engineering technologies and applications to make them more accessible and inexpensive for research and development (R & R&D). Through focused calls for proposals in different areas such as the development of new methods, tools, processes, and platforms for genome editing, improvement of existing genome-editing methods, and novel applications of genome editing technologies in agriculture, bioenergy, environmental research, and human health, efforts have been made to encourage R&D programs in emerging genome engineering technologies and their applications. Despite contributing to one-third of all deaths worldwide, there is no effective treatment, to date, for fibrosis. This study has established PAI-1 as a novel drug target, and pharmacologically targeting this protein may be an effective treatment for combating fibrosis. These factors for CRISPR system research are likely to favor the market's growth.
In the North American region, the US was profoundly affected by the outbreak of the COVID-19 pandemic. The country has marked the highest number of positive patients. Across the nation, various healthcare research centers were working only for research on COVID 19 therapeutics. As the crisis moved forward, healthcare professionals realized that developing novel therapies using innovative technologies is essential to mitigate this unprecedented crisis. In the middle of this situation, governments around the world were not prepared for such a pandemic. The treatment against COVID 19 has been established. Hence, the lack of definitive therapy offers significant opportunities for the genome editing-related market as US FDA has recently approved the use of plasma therapy for critically ill COVID 19 patients. Upcoming stem cell therapies to boost patients' immune systems and eliminate the virus will offer significant growth prospects for the market. For instance, Lattice Biologics, in collaboration with Alumina Partners, has been accelerating phase 1 clinical trials for its stem cell-based AminioBoost therapies of COVID-19. Moreover, the mRNA-based vaccines against the COVID19 have been given emergency use authorization by the regulatory agencies in the region. The active involvement of the government and the associated market players in exploring opportunities for genome editing-related products and services is expected to drive such developments which will add to the future demand for the genome editing market in the North American region.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America genome editing market. The North America genome editing market is expected to grow at a good CAGR during the forecast period.
North America Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
North America Genome Editing Market Segmentation
North America Genome Editing Market – By Technology
- CRISPR
- TALEN
- Antisense
- Other
North America Genome Editing Market – By Application
- Cell Line Engineering
- Genetic Engineering
- Diagnostic Applications
- Drug Discovery
- Others
North America Genome Editing Market – By End User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Clinical Research Organizations (CRO's)
North America Genome Editing Market – By Country
- US
- Canada
- Mexico
North America Genome Editing Market – Companies Mentioned
- THERMO FISHER SCIENTIFIC INC.
- MERCK KGaA
- Lonza
- Horizon Discovery Group plc.
- Integrated DNA Technologies
- GenScript
- New England Biolabs
- Eurofins Scientific
- CRISPR Therapeutics
- Editas Medicine
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Genome Editing Market– By Technology
1.3.2 North America Genome Editing Market– By Application
1.3.3 North America Genome Editing Market– By End User
1.3.4 North America Genome Editing Market– By Country
2. North America Genome Editing Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Genome Editing Market– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinion
5. North America Genome Editing Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Surge in Prevalence of Cancer and Other Genetic Disorders
5.1.2 Ongoing Technological Advancements in Gene-Editing Tools
5.2 Market Restraints
5.2.1 Higher Cost of Genomic Equipment
5.3 Future Trends
5.3.1 Raising Technological Innovations
5.4 Impact Analysis
6. North America Genome Editing Market Analysis
6.1 North America Genome Editing Market Revenue Forecast and Analysis
7. North America Genome Editing Market Revenue and Forecasts to 2028– by Technology
7.1 Overview
7.2 North America Genome Editing Market, By Technology, 2021 & 2028 (%)
7.3 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
7.3.1 Overview
7.3.2 CRISPR: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
7.4 TALEN
7.4.1 Overview
7.4.2 TALEN: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
7.5 Antisense
7.5.1 Overview
7.5.2 Antisense: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
8. North America Genome Editing Market Revenue and Forecasts to 2028 – Application
8.1 Overview
8.2 North America Genome Editing Market Share, By Application - 2021 & 2028 (%)
8.3 Cell Line Engineering
8.3.1 Overview
8.3.2 Cell Line Engineering: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
8.4 Genetic Engineering
8.4.1 Overview
8.4.2 Genetic Engineering: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
8.5 Diagnostic Applications
8.5.1 Overview
8.5.2 Diagnostic Applications: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
8.6 Drug Discovery
8.6.1 Overview
8.6.2 Drug Discovery: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
9. North America Genome Editing Market Revenue and Forecasts to 2028 – End User
9.1 Overview
9.2 North America Genome Editing Market Share by End User - 2021 & 2028 (%)
9.3 Pharmaceutical and Biotechnology Companies
9.3.1 Overview
9.3.2 Pharmaceutical and Biotechnology Companies: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinical Research Organizations (CRO’s)
9.4.1 Overview
9.4.2 Clinical Research Organizations: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
9.5 Academic and Research Institutes
9.5.1 Overview
9.5.2 Academic and Research Institutes: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
10. North America Genome Editing Market Revenue and Forecasts to 2028 – Country Analysis
10.1 Overview:
10.1.1 North America: Genome Editing Market, by Country, 2021 & 2028 (%)
10.1.1.1 US: Genome Editing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 US: Genome Editing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 US: Genome Editing Market, by Technology, 2019–2028 (US$ Million)
10.1.1.1.4 US: Genome Editing Market, by Applications, 2019–2028 (US$ Million)
10.1.1.1.5 US: Genome Editing Market, End User, 2019–2028 (US$ Million)
10.1.1.2 Canada: Genome Editing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Canada: Genome Editing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 Canada: Genome Editing Market, by Technology, 2019–2028 (US$ Million)
10.1.1.2.4 Canada: Genome Editing Market, by Applications, 2019–2028 (US$ Million)
10.1.1.2.5 Canada: Genome Editing Market, End User, 2019–2028 (US$ Million)
10.1.1.3 Mexico: Genome Editing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Mexico: Genome Editing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.3 Mexico: Genome Editing Market, by Technology, 2019–2028 (US$ Million)
10.1.1.3.4 Mexico: Genome Editing Market, by Applications, 2019–2028 (US$ Million)
10.1.1.3.5 Mexico: Genome Editing Market, End User, 2019–2028 (US$ Million)
11. Impact Of COVID-19 Pandemic on North America Genome Editing Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
12. North America Genome Editing Market– Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 THERMO FISHER SCIENTIFIC INC.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 MERCK KGaA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Lonza
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Horizon Discovery Group plc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Integrated DNA Technologies
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 GenScript
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 New England Biolabs
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Eurofins Scientific
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CRISPR Therapeutics
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Editas Medicine
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 Glossary of Terms
LIST OF TABLES
Table 1. US Genome Editing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 2. US Genome Editing Market, by Applications– Revenue and Forecast to 2028 (US$ Million)
Table 3. US Genome Editing Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 4. Canada: Genome Editing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 5. Canada Genome Editing Market, by Applications– Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada Genome Editing Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Mexico: Genome Editing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 8. Mexico Genome Editing Market, by Applications– Revenue and Forecast to 2028 (US$ Million)
Table 9. Mexico Genome Editing Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 10. Organic Developments Done by Companies
Table 11. Inorganic Developments Done by Companies
Table 12. Glossary of Terms, North America Genome Editing Market
LIST OF FIGURES
Figure 1. North America Genome Editing Market Segmentation
Figure 2. North America Genome Editing Market Segmentation, By Country
Figure 3. North America Genome Editing Market Overview
Figure 4. CRISPR Held Largest Share of Technology Segment in North America Genome Editing Market
Figure 5. The US to Show Remarkable Growth During Forecast Period
Figure 6. North America Genome Editing Market, Industry Landscape
Figure 7. North America: PEST Analysis
Figure 8. Expert Opinion
Figure 9. North America Genome Editing Market Impact Analysis of Drivers and Restraints
Figure 10. North America Genome Editing Market– Revenue Forecast and Analysis – 2019-2028
Figure 11. North America Genome Editing Market, by Technology, 2021 & 2028 (%)
Figure 12. CRISPR: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
Figure 13. TALEN: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
Figure 14. Antisense: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
Figure 15. Others: Genome Editing Market Revenue and Forecast to 2028 (US$ Million)
Figure 16. North America Genome Editing Market Share, by Application - 2021 & 2028 (%)
Figure 17. Cell Line Engineering: Genome Editing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Genetic Engineering: Genome Editing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Diagnostic Applications: Genome Editing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Drug Discovery: Genome Editing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Others: Genome Editing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. North America Genome Editing Market Share by End User - 2021 & 2028 (%)
Figure 23. Pharmaceutical and Biotechnology Companies: Genome Editing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. Clinical Research Organizations: Genome Editing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Academic and Research Institutes: Genome Editing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. North America: Genome Editing Market, by Key Country – Revenue (2021) (US$ Million)
Figure 27. North America: Genome Editing Market, by Country, 2021 & 2028 (%)
Figure 28. US: Genome Editing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Canada: Genome Editing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Mexico: Genome Editing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Impact of COVID-19 Pandemic in North American Country Markets
- THERMO FISHER SCIENTIFIC INC.
- MERCK KGaA
- Lonza
- Horizon Discovery Group plc.
- Integrated DNA Technologies
- GenScript
- New England Biolabs
- Eurofins Scientific
- CRISPR Therapeutics
- Editas Medicine
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America genome editing market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America genome editing market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the genome editing market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution